Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma.

Mol Ther Oncol · 2025 · PMC12208612 · PMID 40589567

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp < 0.0001actually significant

Tumor growth curves showed improved tumor control for TILT-517 + anti-PD-1 or anti-PD-L1 compared to their ICIs monotherapy alternatives ( Figures 7 C and 7D), and the combination with anti-PD-L1 displayed highly significant differences ( p < 0.0001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.